Garnier, Lorna, Parant, François, Bulteau, Claire et al. · European journal of obstetrics, gynecology, and reproductive biology · 2024 · DOI
Researchers measured inflammation markers (cytokines) in blood and fluid from the abdomen in women with Essure implants, women with endometriosis, and healthy controls. They found that women with Essure implants had higher levels of two specific inflammation markers (MCP-1 and TNF-α) in their blood compared to controls. These same markers are known to be elevated in fibromyalgia and chronic fatigue syndrome, suggesting they might be relevant to understanding Essure-related symptoms.
This study identifies circulating inflammatory markers (MCP-1 and TNF-α) in Essure-implant patients that overlap with biomarkers documented in ME/CFS and fibromyalgia. For ME/CFS researchers, this cross-condition comparison provides preliminary evidence that systemic cytokine dysregulation may underlie symptom overlap across these conditions, potentially opening new avenues for mechanistic investigation and biomarker development.
This study does not establish that MCP-1 and TNF-α elevation causes Essure-related symptoms, nor does it prove these markers distinguish Essure complications from other causes of chronic inflammation. The cross-sectional design cannot determine whether cytokine elevation precedes symptom onset or is a consequence of symptom burden. No association with symptom severity or clinical improvement was measured, limiting the clinical utility of these markers.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →